Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues
|
|
- Ronald Benson
- 5 years ago
- Views:
Transcription
1 Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program
2 Risks Related to Breast Cancer Advancing Age! Early Menarche! Lack of Exercise! Alcohol! Overweight! Hormone! Replacement! Therapy! Gender! Late Menopause! Diet! Benign Breast Disease! Close Relative! Age at First Birth! Genetics! Education & Income! Ionizing Radiation!???! Genetics! Passive Smoke! Chemicals -Work -Home -Garden -Recreation
3 Timeline of Important Events in DNA Patenting (Top) and the Discovery and Use of Genes Conferring Susceptibility to Breast and Ovarian Cancer (Bottom) June U.S. Supreme Court rules that as nature, genes cannot be patented Kesselheim A and Mello M. N Engl J Med 2010; /NEJMp
4 BRCA1- and BRCA2-Associated Cancers: Lifetime Risk Breast cancer 50%-85% (often early age at onset) Second primary breast cancer 40%-60% Ovarian cancer 15%-45% Absolute risk likely to be higher than 10% - Prostate cancer Absolute risk 10% or lower - Male breast cancer - Fallopian tube cancer - Pancreatic cancer
5 BRCA1 and BRCA2 On chromosomes 17 and 13, respectively Autosomal dominant transmission Proteins have a role in genomic stability >2,000 different mutations, polymorphisms, and variants distributed over both genes BRCA1 Nonsense Missense Splice-site Breast Cancer Information Core
6 BRCA: Selected Examples of Founder Mutations Population BRCA1 Mutations BRCA2 Mutations Ashkenazi Jewish Icelandic 185delAG 5382insC 6174delT 999del5 British 6-kb duplication of exon del4 6503delTT Dutch (Netherlands) Chinese 2804delAA Large deletions of exons 13 & delG Russian 5382insC 4153delA African A. 1832del5 5296del4 943ins10 Hispanic 185delAG deletion exons insT
7 Inherited Genomic Rearrangements of BRCA1 and BRCA2 35/300 (12%) sequence negative high risk families Other: CHEK2 n=14 (5%) TP53 n=3 (1%) Walsh et al, JAMA 295: , 2006
8 k Comprehensive genetic testing includes full sequencing of BRCA1/BRCA2 and detection of large genomic rearrangements.
9 Influence of BRCA1 Genotype on Histopathology in Breast Cancer (BC) Less likely to express estrogen receptor or Her2/neu Have a high nuclear grade Show less tubule formation Have a higher mitotic count Medullary histology more common (~ 6%) More BRCA1 mutations in triple negative DCIS is less associated with BRCA1 than BRCA2 BRCA testing may be appropriate for triple negative BC or early onset DCIS, especially if family history of BC and/or OC Eisinger et al. Cancer Res 56:471, 1996; Claus et al, JAMA 293: , 2005; Breast Cancer Linkage Consortium. Lancet 349:1505, 1997; Kandel (ASCO), 2006
10
11 Genetic Epidemiology of Hereditary Breast Cancer BRCA2 ~30% PTEN TP53 ATM, BRIP1, PALB2, CHEK2 Other Genes (~20%) BRCA1 ~50% 5-10% Hereditary
12 Cowden Syndrome Pedigree Multinodular goiter, dx 25 Follicular thyroid cancer, dx 35 Trichilemmomas, dx 21 Breast cancer, dx 35 Noncarrier Affected Risk for uterine, but not ovarian ca in CS Macrocephaly Papillomatous papules Multinodular goiter, dx 22 Eng C. J Med Genet. 2000;37:
13 Li-Fraumeni Syndrome Bilateral Breast, Breast, 40 Osteosarcoma, 42 Leukemia, 33 TP53-mutation carrier Affected with cancer Breast, 35 Soft tissue sarcoma, 7 Brain tumor, 32 Leukemia, 6 ASCO
14 Emerging Breast Cancer Phenotype in Women with TP53 Germline mutations Cohort of TP53 Carriers N ER+ Her2/neu+ LiFE Consortium 32 84% 63% Masciari et al. BCRT 2012 UK 9 83% Wilson et al. J Med Genet 2010 MDACC/Chi 30 70% 67% Melhem-Bertrandt et al. Cancer 2012 Women < 40 BC, unselected for FHx % 22-33% Collins et al. BCRT 2011; Gonzalez- Angulo et al. Cancer 2012
15 Cancer Screening & Prevention Program Genetic Predisposition Testing Is a Multi-Step Process Identify at-risk patients Obtain informed Provide consent pretest counseling Select and offer test Disclose results Provide post-test counseling and follow-up
16 Estimating Cancer Risk l l l Family History Empiric Data Genetic Testing
17
18 HEREDITARY BREAST AND OVARIAN CANCER Br-! Pm! Br-! 45! ex9-12del + 81! Br-47! ! Br-! Pm! Pr-! 50! Br-49! 43! 41! 45! 47! Ov-38! 28! 25! 23! 1! 9! 11! 9! 24! 26! 18! 21! 25! 31! 30! 33!
19 Clinical management of breast cancer susceptibiity gene mutation-negative patients Negative BRCA and/or multigene panel test NO Member of family w/ known high penetrance mutation? YES Emphasize empirically increased risk of breast and/or ovarian cancer Provide individualized risk-management plan Emphasize risk of sporadic cancer Encourage adherence to population screening guidelines
20 Clinical Management of Mutation-Positive Patient Possible testing for other adult relatives Positive high pentrance gene test result Prophylactic surgery Targeted Therapy Increased surveillance Chemoprevention
21 Warner et al. JCO 19: , 2001
22 MRI and Breast Cancer Detec0on in BRCA Carriers - Sensi0vity N with muta0ons Invasive cancers % by MRI % by mammogram Warner (2004) Kriege (2004) % 31% % 33% MARIBS (2005) % 23% TOTAL % 30% Breast MRI may be considered the standard of care for high risk patients
23 Cumulative incidence of early-stage (stages 0 to I) breast cancer in magnetic resonance imaging (MRI) Warner E et al. JCO 2011;29:
24 Angelina Jolie s double mastectomy puts genetic testing in the spotlight An effective intervention: Study of 483 BRCA carriers: >90% risk reduction Rebbeck, T.R., et al. JCO 22:1055, 2004
25 New Primary Cancer Risk and Modifiers Among 491 BRCA Carriers 10-year contralateral breast cancer risk 43.4% for BRCA1; 34.6% for BRCA2 Age 50 at diagnosis: HR 0.63; 95% CI Tamoxifen use: HR 0.59; 95% CI Oophorectomy: HR 0.44; 95% CI year ovarian cancer risk after breast cancer: 12.7% for BRCA1, 6.8% for BRCA2 (p=0.03) Ovarian cancer was the cause of death in 25% of the Stage I breast cancer patients Metcalfe et al. J Clin Oncol 2004, 22: Gyn Onc 2005; 96:
26 Options for breast cancer patients with BRCA mutations Surgical options for the breast therapeutic mastectomy versus breast conservation therapy on affected breast risk reduction mastectomy on contralateral breast Hormonal risk reduction options BSO tamoxifen Screening mammography MRI
27 Decisions, decisions Oncologic Consultation Treatment Genetic Cancer Risk Assessment Prevention
28 Options for BRCA1, BRCA2 Carrier Prophylactic Oophorectomy Chemoprevention CA125 Screening CASH study. N Engl J Med 316:650, Rosenberg L et al. Am J Epidemiol 139:654, Ursin G et al. Cancer Res 57:3678, Narod et al, NEJM 339:424, 1998Narod SA, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers. J Natl Cancer Inst 2002;94:
29 Oophorectomy Reduces Ovarian Cancer, Breast Cancer, and all cause mortality Greatest breast cancer risk reduction among BRCA1 mutation carriers without a prior dx of breast cancer who had their oophorectomy < age 50 HR: 0.15 (95% CI )
30 PARP inhibition and tumor-selective synthetic lethality DNA damage (SSBs) DNA replication (accumulation of DNA DSBs) PARP PARP inhibition Normal cell with functional HR pathway HR-deficient tumor cell (e.g. BRCA 1/2 -/- ) HR-mediated DNA repair Cell survival Tumor-selective cytotoxicity Cell death Impaired HRmediated DNA repair DSB, double-strand break; HR, homologous recombination SSB, single-strand break Farmer H et al. Nature 2005;434: Bryant HE et al. Nature 2005;434: McCabe N et al. Cancer Res 2006;66:
31 Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer: Best % change from baseline in target BC lesions by prior chemotherapy Olaparib 400 mg bid cohort ORR, n (%) 11 (42) CR, n (%) 1 (4) PR, n (%) 10 (39) Previous anthracycline, taxane and capecitabine Best % change from baseline * * * * * Increasing tumor shrinkage * *Prior platinum Tx Tutt et al. Lancet 2010
32 Protocol NCI #8264: ABT-888 +/- Carbo Adv/Mets BRCA- Breast Cancer Safety Lead-In 21 patients ABT mg BID >2 cycles ABT mg BID + Carbo AUC=5 Post-progression Endpoints: BRCA1 vs. BRCA2 RECIST Criteria PFS ABT-888 single agent; post-progression for combination Safety & Tolerability, Pharmacokinetics Correlative studies will include biomarkers of PARP and carboplatin effect, as well as prospective analyses of mechanism(s) of resistance in vivo selection for BRCA reversion mutants that restore the reading frame and functional domains such as HRR may be one mechanism of drug resistance
33 How Much Breast and Ovarian Cancer Is Hereditary? It depends on what tests you use to answer the question 15% -20% Breast Cancer 5% 7% 10-23% Sporadic Family clusters Hereditary Ovarian Cancer
34 Advances in massively parallel technologies have dramatically reduced the cost of sequencing MacConaill L E JCO 2013;31:
35 Proportions ovarian, fallopian tube, or peritoneal cancer patients with respective germ-line loss-of-function mutations Overall, germline mutation in 23% of unselected OC BRCA genes 74% 10 genes for the next 26% Walsh T et al. PNAS 2011;108:
36
37 R214C G153D Clague et al. RAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families. PloS one. 2011;6(9):e25632.
38 Genetic Heterogeneity and Overlapping Phenotypes = Expanded Differential Diagnoses Pancreatic Ovarian Melanoma CDKN2A BRCA2 PALB2 PRSS1 ATM MMR CHEK2 Colon MMR RAD50 RAD51D BRIP1 BRCA1 MRE11A BRCA2 BARD1 PALB2 RAD51C PTEN TP53 STK11 ATM Breast CHEK2 CDH1 Breast Uterine
39
40 Commercial multigene panels available in U.S. BRCAPlus BreastNext OvaNext CancerNext myrisk ColoNext Coloseq BROCA MDL 30 GeneDx APC x x x x x x x ATM x x x x x x ATR x AXIN2 x x BAP1 x x BARD1 x x x x x x x BIP1 x BLM x BMPR1A x x x x x x x BRCA1 x x x x x x x BRCA2 x x x x x x x BRIP1 x x x x x x x CDH1 x x x x x x x x x x CDK4 x x x CDKN2A x x x CHEK1 x CHEK2 x x x x x x x DCC x EPCAM x x x x x x x x ExOx x FAM175A/Abraxas x x FANCC GALNT12 x GEN1 x GREM1 x HOXB13 x x
41 Weitzel et al. Genetics, Genomics, and Cancer Risk Assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin 2011;61:
42 Cancer Screening & Prevention Program Breast and Ovarian Cancer Screening and Prevention Key advances and evidence for advice: There are advances in protocols for screening (MRI), risk reduction (RRSO, RRM), and targeted treatment Warner et al, 2004; Kriege et al, 2004; Rebbeck et al, 2002, Kauff et al, 2002; Weitzel et al, 2007 GCRA influences surgical decisions in a risk-appropriate way and should be considered for women with newly diagnosed early stage breast cancer and suspicion of BRCA gene mutation Timing of GCRA in the sequence of events in cancer diagnosis and treatment is dependent on both patient and provider variables and limitations Weitzel et al, 2003; Schwartz et al, 2004, 2005.
43 Cancer Screening & Prevention Program Breast and Ovarian Cancer Screening and Prevention Key advances and evidence for advice: BRCA testing for early onset DCIS, and for single cases of BC <50 years if limited family structure; <60 if triple negative Claus et al, 2005; Kandel et al, 2006; Weitzel et al, 2007 Large rearrangements account for a significant proportion of high risk families without sequence detected BRCA mutations Walsh et al, 2006; Weitzel et al, 2007; MGL 2012 Documented efficacy of interventions for BRCA mutation carriers drives medical necessity and liability issues, making GCRA a standard of care GCRA along with risk reduction interventions are cost-effective tools for increasing quality-adjusted life
44 Cancer Screening & Prevention Program Hereditary Cancer Risk Assessment and Management There is clearly a potential to benefit carefully selected and counseled families, with ever broader arrays of genetic tools PALB2 is among the first rare variant genes to acquire adequate data for absolute risk estimation Genetic technologic advances are changing diagnostic approaches Surveillance and prevention can improve survival in at-risk individuals Protocols will need to be adapted to lower risk
Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues
Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Timeline of Important Events in DNA Patenting (Top) and
More informationGermline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues
Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Risk Factors for Breast Cancer Aging Family history Early
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationThe Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine
The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationJill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationCarol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center
Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationHereditary Gynecologic Cancer 15 Years of Progress
Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial
More informationThe Role of genetic Testing for Inherited Prostate Cancer Risk
FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationGenetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel
Genetic counseling and testing Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau, honoraria, consultancy Astra
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationCorporate Medical Policy
Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationpatient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime types
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationInherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions
Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationpatient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention
patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention Know the Basics Breast cancer is the most common cancer in women
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationObjectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice
A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of
More informationManaging Moderate Penetrance
Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationHereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
GENETEST REVIEW Genetics in Medicine Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 Nancie Petrucelli, MS, CGC 1, Mary B. Daly, MD, PhD 2, and Gerald L. Feldman, MD, PhD 3 TABLE
More informationA Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationGenetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
More informationObjectives. Genetics in Cancer Treatment and Prevention. Genes
Objectives Genetics in Cancer Treatment and Prevention Cheryl LaFlore, ARNP, MSN, BC Understand how to integrate genetic and genomic information into oncology nursing practice Define the role of an oncology
More informationHereditary Cancer Update Strengthening Linkages Workshop April 22, 2017
Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationManagement of BRCA mutation carriers
Management of BRCA mutation carriers Clinical Case Presentation Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Oncology Institute Sheba Medical Center, Israel esmo.org DISCLOSURES
More informationOutline. Identifying your risk for hereditary breast or ovarian cancer. Genetics 101. What causes cancer? Genetics
Identifying your risk for hereditary breast or ovarian cancer David Andorsky, MD Breanna Roscow, MS, CGC 303-993-0161 Outline Genetics and biology of hereditary cancer syndromes BRCA1 and BRCA2 Genetic
More informationGenetic testing for hereditary cancer
Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of
More informationRisk-reducing Surgery in BRCA mutation carriers
Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS Overview of HBOC
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationBreast MRI: Friend or Foe?
Breast MRI: Friend or Foe? UCSF Postgraduate Course May 18, 2013 Cheryl Ewing, MD Clinical Professor of Surgery UCSF Department of Surgery APPLEGATE HAS DOUBLE MASTECTOMY IN CANCER SCARE DIAGNOSED WITH
More informationThe impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice
The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice Use BRACAnalysis as a guide in your medical and surgical management BRACAnalysis testing
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2017 Origination: 7/2013 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationBRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI
BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI DR KIRTI CHADHA MD (Path), PDCC (Oncopath & Oncohemat) CONSULTANT SURGICAL PATHOLOGIST NATIONAL COORDINATOR,SURGICAL PATHOLOGY
More informationLearn your genetic risk for the most common hereditary cancers.
Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,
More informationUW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA
Supplementary Table 1. Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations. ID Site Stage Grade Histology Tumor Age Germline mutation(s) a Somatic HR mutation(s)
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: CATEGORY: Laboratory Test
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS POLICY NUMBER: 2.02.06 CATEGORY: Laboratory Test EFFECTIVE DATE: 01/17/02 REVISED DATE: 08/21/03, 09/16/04, 08/18/05, 06/15/06, 04/17/14,
More informationGenetics & Precision Medicine Cancer Care
Genetics & Precision Medicine Cancer Care Johnathan M. Lancaster, MD PhD Chief Medical Officer Myriad Genetics Copyright 2015 Myriad Genetics, Inc., all rights reserved. www.myriad.com. Precision Medicine
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)
More informationHereditary Cancer Update: What do GPOs need to know?
Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to
More informationHereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14, 09/15/15.
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationOvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer
patient guide OvaNext genetic testing for hereditary breast, ovarian, and uterine cancer Because knowing your risk can mean early detection and prevention About half of the women diagnosed with uterine
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationMP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019
More informationFamily Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool
Besides the BRCA genes, what else to consider in hereditary breast and ovarian cancer? Laurie M. Connors DNP, APNG, FNP-BC, AGN-BC Objectives Evaluate personal & family history to assess risk for hereditary
More informationRole of genetic testing in familial breast cancer outside of BRCA1 and BRCA2
Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? A Patient s Guide to Hereditary Breast and Ovarian Cancer Syndrome What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Versions 2003 2012: Schmutzler with Albert / Blohmer /
More information